

TUFTS COLLEGE DENTAL SCHOOL
418 HUNTINGTON AVENUE
BOSTON, MASSACHUSETTS

AD

November 12, 1948

Food and Drug Administration
Washington, D.C.

NDA 6488
4

Dear Sirs:

At the suggestion of Mr. Erik Bjaringer of the Astra Company we are writing to summarize our findings to date on the use of Xylocaine as a local anesthetic and our observations on its clinical safety.

To date 170 patients have been studied. Approximately one-half of these have been cases in which Xylocaine was employed as a local anesthetic and in the other half Procaine Hydrochloride was used. These tests are being carried out blind, and it is our intention to complete the series of 200 cases before the operators are allowed to learn which of the materials have been used on a particular day. The clinical observations include blood pressure measurements and pulse rate before, and one and five minutes after administration of the anesthetic. The patients are questioned and observed for any untowards symptoms such as palpitation, dizziness, and feeling of faintness. There are certain deductions, however, which can properly be made from the experiments without having to know the exact findings for Xylocaine and Procaine separately.

In no instance in the 170 cases studied was there any evidence of toxic symptoms. The rapidity and depths of anesthesia was satisfactory in all cases.

Very truly yours,

Joseph P. Lazansky

Joseph P. Lazansky

JPL/bma

225.07